Datao Liu
5 Papers
7 Citations
Datao Liu is an academic researcher. The author has contributed to research in topics: Medicine & Antibody. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys.
Shuang Wang,Yun Peng,Rongjuan Wang,Shasha Jiao,Min Wang,Weijin Huang,Chao Shan,Wen Jiang,Zepeng Li,Chunying Gu,Ben Chen,Xue Hu,Yanfeng Yao,Juan Min,Huajun Zhang,Ying Chen,Ge Gao,Peipei Tang,Gang Li,An Wang,Lan Wang,Jinchao Zhang,Shuo Chen,Xun Gui,Zhiming Yuan,Datao Liu +25 more
TL;DR: A monoclonal antibody, MW05, with SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor is reported.
CoVac501, a self-adjuvanting peptide vaccine conjugated with TLR7 agonists, against SARS-CoV-2 induces protective immunity
Yiru Long,Jianhua Sun,Tian-Zhang Song,Tingting Liu,Feng Tang,Xinxin Zhang,Longfei Ding,Yunqiu Miao,Wei Zhou,Xiaoyan Pan,Qi An,Mian Qin,Xiankun Tong,Xionghua Peng,Peng Yu,Peng Zhu,Jianming Xu,Xiaogang Zhang,Yachun Zhang,Datao Liu,Ben Chen,Huilin Chen,Lei Zhang,Gengfu Xiao,Jianping Zuo,Wei-Ping Tang,Jie Zhou,Heng Li,Zhijian Xu,Hong-Yi Zheng,Xin-Yan Long,Qiu Yan Qin,Yong Gan,Jin Ren,Wei Huang,Yongchui Zheng,Guangyi Jin,Likun Gong +37 more
TL;DR: In this paper , a self-adjuvanting peptide vaccine conjugated with Toll-like receptor 7 (TLR7) agonists was proposed to achieve adequate herd immunity and end the SARS-CoV-2 pandemic.
An antibody-dependent enhancement (ADE) activity eliminated neutralizing antibody with potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
Shuang Wang,Yun Peng,Rongjuan Wang,Shasha Jiao,Min Wang,Weijin Huang,Chao Shan,Wen Jiang,Zepeng Li,Chunying Gu,Ben Chen,Xue Hu,Yanfeng Yao,Juan Min,Huajun Zhang,Ying Chen,Ge Gao,Peipei Tang,Gang Li,An Wang,Lan Wang,Shuo Chen,Xun Gui,Jinchao Zhang,Zhiming Yuan,Datao Liu +25 more
TL;DR: A monoclonal antibody, MW05, is reported showing high SARS-CoV-2 neutralizing activity by disrupting the interaction of receptor binding domain (RBD) with angiotensin-converting enzyme 2 (ACE2) receptor by introducing the LALA mutation to the Fc region (MW05/LALA).
7
Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers.
Wei Zhou,Peng Fang,Dong-An Yu,Meng You,Long Yin,Fei Mei,Zhenzhen Wang,Hui Xu,Xiaohong Xu,Jianjun Bi,Jin Wang,Lanping Ma,Xin Wang,Lin Chen,Yonglian Zhang,Xiaowei Cen,Xi Zhu,Liguang Lou,Datao Liu,Xiaoding Tan,Jinliang Yang,Tao Meng,Jingkang Shen +22 more
TL;DR: A second generation nectin-4-specific drug, 9MW2821, based on interchain disulfide drug conjugate technology was proposed in this article , which contained a site-specifically conjugated humanized antibody and the cytotoxic moiety monomethyl auristatin E.
Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcγRIIB and virus-antibody complex with bivalent interaction
Shuang Wang,Junchao Wang,Xiaojuan Yu,Wen Jiang,Shuo Chen,Rongjuan Wang,Mingzhu Wang,Shasha Jiao,Ying Yang,Wenbo Wang,Huilin Chen,Ben Chen,Chunying Gu,Chang Liu,An Wang,Min Wang,Gang Li,Cuicui Guo,Datao Liu,Jinchao Zhang,Min Zhang,Lan Wang,Xun Gui +22 more
TL;DR: In this article , two neutralizing mAbs, MW01 and MW05, could enhance the infection of SARS-CoV-2 pseudovirus on FcγRIIB-expressing B cells.